Merck's experimental eye drug meets goal in trial, but raises safety concerns
JasonDoiy/iStock Unreleased via Getty Images
Merck (MRK) said its experimental eye drug remigromig improved vision in patients with a diabetes-related eye disease, meeting the main goal of a late-stage clinical trial. However, patients receiving the treatment experienced higher rates of a potentially serious eye complication than those
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.